> Details

Sehouli, Jalid; Stengel, Dirk; Harter, Philipp; Kurzeder, Christian; Belau, Antje; Bogenrieder, Thomas; Markmann, Susanne; Mahner, Sven; Mueller, Lothar; Lorenz, Ralf; Nugent, Andreas; Wilke, Jochen; Kuznik, Andreas; Doering, Gabriele; Wischnik, Arthur; Sommer, Harald; Meerpohl, Hans-Gerd; Schroeder, Willibald; Lichtenegger, Werner; Oskay-Oezcelik, Guelten

Topotecan Weekly Versus Conventional 5-Day Schedule in Patients With Platinum-Resistant Ovarian Cancer: A Randomized Multicenter Phase II Trial of the North-Eastern German Society of Gynecological Oncology Ovarian Cancer Study Group

Reference
management

Bookmarks

Remove from
bookmarks

Share this on Whatsapp

Close

Bookmarks



You can manage bookmarks using lists, please log in to your user account for this.
  • Media type: E-Article
  • Title: Topotecan Weekly Versus Conventional 5-Day Schedule in Patients With Platinum-Resistant Ovarian Cancer: A Randomized Multicenter Phase II Trial of the North-Eastern German Society of Gynecological Oncology Ovarian Cancer Study Group
  • Contributor: Sehouli, Jalid; Stengel, Dirk; Harter, Philipp; Kurzeder, Christian; Belau, Antje; Bogenrieder, Thomas; Markmann, Susanne; Mahner, Sven; Mueller, Lothar; Lorenz, Ralf; Nugent, Andreas; Wilke, Jochen; Kuznik, Andreas; Doering, Gabriele; Wischnik, Arthur; Sommer, Harald; Meerpohl, Hans-Gerd; Schroeder, Willibald; Lichtenegger, Werner; Oskay-Oezcelik, Guelten
  • imprint: American Society of Clinical Oncology (ASCO), 2011
  • Published in: Journal of Clinical Oncology
  • Language: English
  • DOI: 10.1200/jco.2009.27.8911
  • ISSN: 0732-183X; 1527-7755
  • Origination:
  • Footnote:
  • Description: <jats:sec><jats:title>Purpose</jats:title><jats:p> Weekly administration of topotecan (Tw) is less toxic and widely considered a better treatment option than conventional 5-day therapy (Tc) in women with platinum-resistant recurrent ovarian cancer. We conducted a randomized phase II trial (TOWER [Topotecan Weekly Versus Conventional 5-Day Schedule in Patients With Platinum-Resistant Ovarian Cancer]) to better define the ratio between benefits and risks with either treatment approach. </jats:p></jats:sec><jats:sec><jats:title>Patients and Methods</jats:title><jats:p> Patients were randomly assigned to two independent two-stage protocols of Tw (4 mg/m<jats:sup>2</jats:sup>/wk administered on days 1, 8, and 15) or Tc (1.25 mg/m<jats:sup>2</jats:sup>/d on days 1 to 5). We evaluated risk ratios (RRs) for the primary end point of clinical benefit (complete response, partial response, and stable disease), the duration of progression-free survival (PFS) and overall survival (OS), associated hazard ratios (HRs), and RRs of toxicity with 95% CIs. </jats:p></jats:sec><jats:sec><jats:title>Results</jats:title><jats:p> In total, 194 patients were randomly assigned at 54 centers to Tw (n = 97) or Tc (n = 97). Clinical benefit was observed in 36 of 76 (47%; 95% CI, 36% to 59%) Tw and 46 of 80 (58%; 95% CI, 46% to 68%) Tc patients (RR, 1.21; 95% CI, 0.90 to 1.64; P = .205). Patients in the Tw group had a slightly shorter PFS (HR, 1.29; 95% CI, 0.96 to 1.76) but similar OS (HR, 1.04; 95% CI, 0.74 to 1.45) compared with Tc. Tw was associated with significantly lower risks of anemia (RR, 0.35; 95% CI, 0.16 to 0.79), neutropenia (RR, 0.38; 95% CI, 0.23 to 0.65), and thrombocytopenia (RR, 0.23; 95% CI, 0.09 to 0.57). </jats:p></jats:sec><jats:sec><jats:title>Conclusion</jats:title><jats:p> With regard to effectiveness in terms of response and PFS, Tc remains the standard of care in patients with platinum-resistant recurrent ovarian cancer. However, comparable OS rates and a favorable toxicity profile make Tw another viable treatment option in this setting. </jats:p></jats:sec>
  • Access State: Open Access